Skip to main content
SpringerLink
Log in

Stereotactic Body Radiation Therapy (SBRT) for Lung Metastases

  • Chapter
  • First Online:
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

  • 1405 Accesses

Abstract

Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective option for ablation of well-localized primary and secondary lung tumors. Most published clinical trials and series of lung SBRT to date have been dose-escalation or single-arm studies, which collectively demonstrate local control rates exceeding 80% and a low incidence of high-grade toxicity. More recently, phase II randomized trials of consolidative locally ablative therapy in metastatic NSCLC, treating both intra- and extra-thoracic disease, have demonstrated improvements in progression-free survival and a reduction in new metastatic lesions. Concurrently, the rapidly evolving landscape of targeted agents and immunotherapeutics has led to an expanding role of SBRT in the treatment of oligoprogressive metastatic disease in an effort to extend access to effective, well-tolerated systemic therapies. As the role and survival impact of lung SBRT continues to be defined in various settings, careful patient selection and treatment delivery techniques remain paramount to maximizing the benefit of local tumor ablation in patients with metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res. 2015;21(23):5198–204.

    Article  CAS  PubMed  Google Scholar 

  2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504–35.

    Article  PubMed  Google Scholar 

  3. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(5):295–301.

    Article  PubMed  Google Scholar 

  4. De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Pechoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28(36):5301–10.

    Article  PubMed  Google Scholar 

  5. De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Pechoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124(1):1–10.

    Article  PubMed  Google Scholar 

  6. Seppenwoolde Y, Shirato H, Kitamura K, Shimizu S, van Herk M, Lebesque JV, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53(4):822–34.

    Article  PubMed  Google Scholar 

  7. Plathow C, Ley S, Fink C, Puderbach M, Hosch W, Schmahl A, et al. Analysis of intrathoracic tumor mobility during whole breathing cycle by dynamic MRI. Int J Radiat Oncol Biol Phys. 2004;59(4):952–9.

    Article  PubMed  Google Scholar 

  8. Negoro Y, Nagata Y, Aoki T, Mizowaki T, Araki N, Takayama K, et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys. 2001;50(4):889–98.

    Article  CAS  PubMed  Google Scholar 

  9. Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008;70(5):1571–8.

    Article  PubMed  Google Scholar 

  10. Harada K, Katoh N, Suzuki R, Ito YM, Shimizu S, Onimaru R, et al. Evaluation of the motion of lung tumors during stereotactic body radiation therapy (SBRT) with four-dimensional computed tomography (4DCT) using real-time tumor-tracking radiotherapy system (RTRT). Phys Med. 2016;32(2):305–11.

    Article  PubMed  Google Scholar 

  11. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys. 2006;33(10):3874–900.

    Article  PubMed  Google Scholar 

  12. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.

    Article  PubMed  Google Scholar 

  13. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84.

    Article  PubMed  Google Scholar 

  14. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.

    Article  PubMed  Google Scholar 

  16. Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM. Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy. Int J Radiat Oncol Biol Phys. 2015;92(2):325–31.

    Article  PubMed  Google Scholar 

  17. Verma V, Shostrom VK, Kumar SS, Zhen W, Hallemeier CL, Braunstein SE, et al. Multi-institutional experience of stereotactic body radiotherapy for large (≥ 5 centimeters) non–small cell lung tumors. Cancer. 2017;123(4):688–96.

    Article  PubMed  Google Scholar 

  18. Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018;36(7):710–9.

    Article  CAS  PubMed  Google Scholar 

  19. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53.

    Article  PubMed  Google Scholar 

  20. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(2):376–81.

    Article  PubMed  Google Scholar 

  21. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non–small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):117–25.

    Article  PubMed  Google Scholar 

  22. Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. 2017;98(3):622–31.

    Article  PubMed  Google Scholar 

  23. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non–small-cell lung cancer. J Clin Oncol. 2014;32(34):3824–30.

    Article  PubMed  Google Scholar 

  24. Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016;95(2):632–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One. 2016;11(6):e0157164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56(1):126–35.

    Article  PubMed  Google Scholar 

  27. Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006;45(7):808–17.

    Article  PubMed  Google Scholar 

  28. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1(8):802–9.

    Article  PubMed  Google Scholar 

  29. Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys. 2015;91(2):337–43.

    Article  PubMed  Google Scholar 

  30. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86.

    Article  PubMed  Google Scholar 

  31. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(5):1516–22.

    Article  PubMed  Google Scholar 

  32. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–70.

    Article  PubMed  Google Scholar 

  33. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2017;4:e173501.

    Article  PubMed Central  Google Scholar 

  35. Kim MS, Yoo SY, Cho CK, Yoo HJ, Choi CW, Seo YS, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology. 2009;76(3):212–9.

    Article  PubMed  Google Scholar 

  36. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Carvajal C, Navarro-Martin A, Cacicedo J, Ramos R, Guedea F. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. J BUON. 2015;20(1):158–65.

    PubMed  Google Scholar 

  38. Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92(4):837–42.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Jung J, Song SY, Kim JH, Yu CS, Kim JC, Kim TW, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol. 2015;10:238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Qiu H, Katz AW, Chowdhry AK, Usuki KY, Singh DP, Metcalfe S, et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol. 2018;41(1):53–8.

    PubMed  Google Scholar 

  41. Kinj R, Bondiau PY, Francois E, Gerard JP, Naghavi AO, Leysalle A, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy. Clin Colorectal Cancer. 2017;16(3):e211–e20.

    Article  PubMed  Google Scholar 

  42. Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer. 2017;16(1):58–64.

    Article  PubMed  Google Scholar 

  43. Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):1044–52.

    Article  PubMed  Google Scholar 

  44. Helou J, Thibault I, Poon I, Chiang A, Jain S, Soliman H, et al. Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter. Int J Radiat Oncol Biol Phys. 2017;98(2):419–27.

    Article  PubMed  Google Scholar 

  45. Dhakal S, Corbin KS, Milano MT, Philip A, Sahasrabudhe D, Jones C, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012;82(2):940–5.

    Article  PubMed  Google Scholar 

  46. Mehta N, Selch M, Wang PC, Federman N, Lee JM, Eilber FC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma. 2013;2013:360214.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Navarria P, Ascolese AM, Cozzi L, Tomatis S, D’Agostino GR, De Rose F, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015;51(5):668–74.

    Article  PubMed  Google Scholar 

  48. Frakulli R, Salvi F, Balestrini D, Parisi A, Palombarini M, Cammelli S, et al. Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res. 2015;35(10):5581–6.

    CAS  PubMed  Google Scholar 

  49. Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol. 2016;114(1):65–9.

    Article  PubMed  Google Scholar 

  50. Soyfer V, Corn BW, Shtraus N, Honig N, Meir Y, Kollender J, et al. Single-institution experience of SBRT for lung metastases in sarcoma patients. Am J Clin Oncol. 2017;40(1):83–5.

    Article  PubMed  Google Scholar 

  51. Franceschini D, Cozzi L, De Rose F, Navarria P, Franzese C, Comito T, et al. Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. J Cancer Res Clin Oncol. 2017;143(7):1293–9.

    Article  PubMed  Google Scholar 

  52. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol. 2009;4(7):838–44.

    Article  PubMed  Google Scholar 

  53. Guckenberger M, Klement RJ, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, et al. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85(4):1074–81.

    Article  PubMed  Google Scholar 

  54. Stone B, Mangona VS, Johnson MD, Ye H, Grills IS. Changes in pulmonary function following image-guided stereotactic lung radiotherapy: neither lower baseline nor post-SBRT pulmonary function are associated with worse overall survival. J Thorac Oncol. 2015;10(12):1762–9.

    Article  CAS  PubMed  Google Scholar 

  55. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, et al. A dose–volume analysis of radiation pneumonitis in non–small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):457–62.

    Article  PubMed  Google Scholar 

  56. Pollom EL, Chin A, Diehn M, Loo BW, Chang DT, editors. Normal tissue constraints for abdominal and thoracic SBRT. Semin Radiat Oncol. 2017;27(3):197–208. Elsevier.

    Google Scholar 

  57. Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies. Int J Radiat Oncol Biol Phys. 2016;95(5):1357–66.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012;7(1):152.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, et al. Chest wall volume receiving > 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(3):796–801.

    Article  PubMed  Google Scholar 

  60. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93(4):757–64.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry RC, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol. 2009;93(3):408–13.

    Article  PubMed  Google Scholar 

  62. Din S, Yamada J, Yorke E, Foster A, Poppens E, Thompson M, et al. Brachial plexopathy after high-dose stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2013;87(2):S518–S9.

    Article  Google Scholar 

  63. Timmerman RD, editor. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215–22. Elsevier.

    Google Scholar 

  64. Duijm M, Schillemans W, Aerts JG, Heijmen B, Nuyttens JJ, editors. Dose and volume of the irradiated main bronchi and related side effects in the treatment of central lung tumors with stereotactic radiotherapy. Semin Radiat Oncol. 2016;26(2):140–8. Elsevier.

    Google Scholar 

  65. Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2016;6(2):e27–33.

    Article  PubMed  Google Scholar 

  66. Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “Ultracentral” non-small cell lung cancer. J Thorac Oncol. 2016;11(7):1081–9.

    Article  PubMed  Google Scholar 

  67. Repka MC, Aghdam N, Kataria SK, Campbell L, Suy S, Collins SP, et al. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation. Radiat Oncol. 2017;12(1):162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol. 2018;30(1):5–14.

    Article  CAS  Google Scholar 

  69. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007;2:21.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med. 1977;86(1):81–92.

    Article  CAS  PubMed  Google Scholar 

  71. Graves PR, Siddiqui F, Anscher MS, Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol. 2010;20(3):201–7.

    Article  PubMed  Google Scholar 

  72. Ozturk B, Egehan I, Atavci S, Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004;58(1):213–9.

    Article  CAS  PubMed  Google Scholar 

  73. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    Article  CAS  PubMed  Google Scholar 

  74. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.

    Article  CAS  PubMed  Google Scholar 

  75. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.

    Article  CAS  PubMed  Google Scholar 

  76. Rusthoven CG, Yeh N, Gaspar LE. Radiation therapy for oligometastatic non-small cell lung cancer: theory and practice. Cancer J. 2015;21(5):404–12.

    Article  CAS  PubMed  Google Scholar 

  77. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84(1):324–38.

    Article  PubMed  Google Scholar 

  81. de Baere T, Auperin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204(1):49–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–68.

    Article  CAS  PubMed  Google Scholar 

  85. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (Baltimore, Md: 1950). 2005;174(12):7516–23.

    Article  CAS  Google Scholar 

  86. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  PubMed  Google Scholar 

  88. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol. 2014;9:210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Nguyen TK, Senan S, Bradley JD, Franks K, Giuliani M, Guckenberger M, et al. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: findings of an International Delphi Consensus Study. Pract Radiat Oncol. 2018;8(2):e71–8.

    Article  PubMed  Google Scholar 

  91. Huang K, Senthi S, Palma DA, Spoelstra FO, Warner A, Slotman BJ, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol. 2013;109(1):51–7.

    Article  PubMed  Google Scholar 

  92. Ronden MI, van Sornsen de Koste JR, Johnson C, Slotman BJ, Spoelstra FOB, Haasbeek CJA, et al. Incidence of high-risk radiologic features in patients without local recurrence after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;100(1):115–21.

    Article  CAS  PubMed  Google Scholar 

  93. Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102(3):335–42.

    Article  PubMed  Google Scholar 

  94. Chang JY, Bezjak A, Mornex F. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2015;10:577–85.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA

    William A. Stokes, Sameer K. Nath & Chad G. Rusthoven

  2. Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, CO, USA

    Tyler P. Robin

Authors
  1. William A. Stokes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tyler P. Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sameer K. Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chad G. Rusthoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chad G. Rusthoven .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Radiation Oncology, Mayo Clinic School of Medicine Radiation Oncology, Jacksonville, FL, USA

    Daniel M. Trifiletti

  2. Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Samuel T. Chao

  3. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    Arjun Sahgal

  4. University of Virginia, Departments of Neurological Surgery and Radiation Oncology, Charlottesville, VA, USA

    Jason P. Sheehan

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stokes, W.A., Robin, T.P., Nath, S.K., Rusthoven, C.G. (2019). Stereotactic Body Radiation Therapy (SBRT) for Lung Metastases. In: Trifiletti, D., Chao, S., Sahgal, A., Sheehan, J. (eds) Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-16924-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16924-4_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16923-7

  • Online ISBN: 978-3-030-16924-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation